about
A simple sign for recognizing off-axis OCT measurement beam placement in the context of multicentre studiesDisease course heterogeneity and OCT in multiple sclerosisPlasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALSThe Historical Origin of the Pulfrich Effect: A Serendipitous Astronomic Observation at the Border of the Milky WaySpectrophotometry for XanthochromiaOptic flow induced nystagmus.CSF biomarkers for improved prognostic accuracy in acute CNS disease.A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot studyThe use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritisAxonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter.The OSCAR-IB consensus criteria for retinal OCT quality assessmentDiagnosis and classification of autoimmune optic neuropathy.Cerebrospinal fluid ferritin level, a sensitive diagnostic test in late-presenting subarachnoid hemorrhage.In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study.Optic Neuritis: Another Dickensian DiagnosisEffects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients.Recurrent ptosis due to myopathy of the levator palpebrae superioris.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases.Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.Visual pathway neurodegeneration winged by mitochondrial dysfunction.Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.The prevalence of microcystic macular changes on optical coherence tomography of the macular region in optic nerve atrophy of non-neuritis origin: a prospective study.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.Axonal damage and outcome in subarachnoid haemorrhage.Central and paracentral visual field defects and driving abilities.Elevated vitreous body glial fibrillary acidic protein in retinal diseases.Spectrophotometry for cerebrospinal fluid pigment analysis.Clinical disorders affecting mesopic vision.Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report.The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrestTiming of retinal neuronal and axonal loss in MS: a longitudinal OCT study.Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?Isolated, relapsing and progressive demyelinating diseases of the central nervous system.
P50
Q27312517-B41563D9-E1D1-4C11-87DC-F4E0A4565163Q28305473-8EB5A259-6276-4647-A253-998C39D01AC8Q28481340-B25FB9AA-7825-4E1B-9175-8EFF21AC047AQ30052311-3500FB62-6BBD-49BB-973D-B51BFA31FA15Q30052578-A9EEE07B-B68D-4CB5-9C52-C71ABF50430AQ30478589-4F523CE7-8589-443C-BACC-88DD15F2ED0CQ33313220-B773A1C0-D174-4378-A8B2-6E500601878DQ33731693-B87CDBD3-929A-40B0-B7B3-6A34735A9F09Q33753792-1A3274E9-40F2-4A0C-986D-D3521F61C59BQ34005484-078D7547-FC18-4040-A887-EC23011688CDQ34220288-7C00999C-F631-4BD9-A35C-317B1B843A54Q34247079-72942058-C2DD-4A23-97A2-CC2E1D14FB09Q34397817-910B37F5-4C3D-4D7F-946A-0DB814E2F1D4Q34504592-17256417-83D8-46AE-855A-4A1D70242962Q34538926-255C4FCA-60CB-4C3B-AE5A-0ABD15547501Q34550729-206ABBE0-5A59-40B8-A949-A7C2836850C3Q34577625-82C41A83-C2DD-4484-B692-8FFC3DEEECACQ34606170-78CA9A22-1E12-4B64-A667-72FFB7651E5DQ34617199-81559726-1346-4B5A-9B3A-88DB51236C20Q34619162-51E7E40B-AC6C-4F9D-8117-C027482ED44FQ34785270-FC557AFF-C5C9-46B3-A7C1-C59A6F6953F1Q35000781-39B08FC3-A8CB-4EEF-835A-9CF145545860Q35115909-34FB8283-EC35-48A1-8194-3327A2226421Q35377133-29CFB536-D807-4E06-90D3-51B3AC8637ECQ35485799-BC7E97BB-84B2-44F1-84AD-52F832DFB6B1Q35550715-6F6A6F44-B761-481D-8A0E-6919A1514DFEQ35679358-9A00BD18-B291-4B27-BD72-78F1CF947867Q35686186-B6B7B4C3-F1F3-4F29-AAE9-BFFC45C01510Q36142095-2C7B63EC-23D6-4AE1-B3B1-8F6559AA7701Q36222758-9DA4C000-2B04-49FE-8376-953E82FBA1A2Q36300501-CED0D27C-FC08-4176-8164-58E52503732DQ36455048-F06FA8B1-103A-44EF-BA43-D9252E980F5BQ36473176-483FBBDE-1683-43A9-BE4B-C79B83E5A4BBQ36496440-E5C643CA-A655-4003-9B9C-46B2049C3C83Q36500261-9943F1D1-313A-4475-BA95-E32198B70739Q36863037-DCFFF5FD-8829-4F72-B7A6-E8B30420760FQ36925772-B7D67D5E-B16D-4F53-B130-365E261133E2Q37056744-623AE36D-617C-4797-977D-C4D6D1C2717CQ37408133-85A7936D-773D-40AE-B8C5-F854B9680C08Q37419061-CC216E2F-057E-4DF6-B732-B769172FD2C3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Axel Petzold
@ast
Axel Petzold
@en
Axel Petzold
@es
Axel Petzold
@nl
Axel Petzold
@sl
type
label
Axel Petzold
@ast
Axel Petzold
@en
Axel Petzold
@es
Axel Petzold
@nl
Axel Petzold
@sl
prefLabel
Axel Petzold
@ast
Axel Petzold
@en
Axel Petzold
@es
Axel Petzold
@nl
Axel Petzold
@sl
P214
P244
P1053
C-1090-2009
P106
P1153
7006826396
P21
P213
0000 0000 1566 1638
P214
P244
n2016180204
P31
P3829
P496
0000-0002-0344-9749
P734
P735
P7859
lccn-n2016180204